haloperidol / Generic mfg. - LARVOL DELTA

First-generation antipsychotic shortages in the United States: Utilization and switching patterns. (PubMed, Explor Res Clin Soc Pharm) - "Most were receiving haloperidol (n = 52,344, 54.5%) and perphenazine (n = 16,966, 17.7%). Switching was common among individuals receiving thiothixene (32.8%), trifluoperazine (55.2%), and molindone (100%). Time to first switch ranged from 22 (standard deviation [SD]: 21) to 103 (SD: 66) days. Shortages of FGAs may influence patients' switching to other agents, including second generation antipsychotics."

Journal • CNS Disorders

NS4: Management of nausea in cancer patients – Nausea study 4 pilot (ANZCTR) - P2 | N=24 | Completed | Sponsor: The University of Technology Sydney | Recruiting ➔ Completed

Trial completion • Oncology

Clinical trial to study the effect of an already authorized drug on othernpathologies by administering it to people with a recent diagnosis ofnschizophrenia. (clinicaltrialsregister.eu) - P2/3 | N=37 | Recruiting | Sponsor: Fundacion Para La Gestion De La Investigacion En Salud De Sevilla | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Psychiatry • Schizophrenia

Non-ketotic hyperglycaemic hemichorea as the first manifestation of undiagnosed diabetes mellitus in an elderly patient. (PubMed, Endocrinol Diabetes Metab Case Rep) - "Treatment with insulin, haloperidol, and tetrabenazine achieved a gradual symptomatic improvement, with a marked reduction in involuntary movements at three months, although resolution was protracted compared to the typical cases. Some patients can achieve symptom resolution by glucose control alone. However, the majority require additional anti-chorea medications."

Journal • CNS Disorders • Diabetes • Metabolic Disorders • Movement Disorders • Vascular Neurology

Neuroprotective effects of Premna integrifolia nano-phytosomes in haloperidol-induced Parkinson's rat model: A computational-guided Olivil nanoformulation delivery approach. (PubMed, Metab Brain Dis) - No abstract available

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

When Agitation Meets Intoxication: A Retrospective Comparison of Intramuscular Olanzapine and Haloperidol Among Patients With and Without Substance Use in a Psychiatric Emergency Service. (PubMed, Subst Use Addctn J) - "Patients with active substance use exhibited similar or greater responses to standard IM treatment for agitation without increased safety concerns. Findings support potential safety and efficacy of common pharmacologic approaches in this high-risk population, though a modest single-site cohort may limit generalizability. There is a need for prospective, multisite replication."

Journal • Retrospective data • Psychiatry

A decade of change in delirium management: Temporal trends in psychotropic recommendations in a tertiary care hospital. (PubMed, J Psychosom Res) - "Delirium consultation practice has shifted toward more conservative, guideline-concordant recommendations, characterized by reduced haloperidol use, increased reliance on olanzapine, melatonin, and non-pharmacological strategies. Whether these trends translate into improved patient outcomes remains to be established and warrants prospective investigation."

Journal • CNS Disorders • Psychiatry

AGITATION SEVERITY AND PSYCHOTROPIC USE IN DELIRIUM SUPERIMPOSED ON DEMENTIA: FINDINGS FROM THE DELDEM COHORT (ADPD 2026) - "Conclusions DSD is associated with heightened agitation and increased psychotropic exposure, underscoring safety concerns and the need for tailored non-pharmacological strategies."

Alzheimer's Disease • CNS Disorders • Dementia

NEUROPROTECTIVE EFFICACY OF NOVEL COUMARIN DERIVATIVES IN A HALOPERIDOL-INDUCED PARKINSONIAN RAT MODEL (ADPD 2026) - "The synthesized coumarin derivatives, particularly SDS-20244, exhibit significant neuroprotective activity in haloperidol-induced Parkinsonian models, likely through antioxidant mechanisms and modulation of dopaminergic neurotransmission. These findings support further investigation of coumarin scaffolds as potential therapeutics for neuroleptic-induced neurodegeneration and PD."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • ACHE

Use of Haloperidol For the Management of Cannabinoid Hyperemesis Syndrome: Comparing Pediatric and Adult Patient Characteristics (PAS 2026) - No abstract available

Clinical • Pediatrics

Impact of Haloperidol on Emergency Department Outcomes in Pediatric Cannabis Hyperemesis Syndrome (PAS 2026) - No abstract available

Clinical • Pediatrics

Olanzapine-induced renal phospholipidosis (NKF-SCM 2026) - "METHODS/CASE SUMMARY A 62-year-old man with lung adenocarcinoma on pembrolizumab developed AKI on progressive CKD...He received IV methylprednisolone with improvement to 2.5 mg/dL, but creatinine rose during prednisone tapering. Infliximab produced partial improvement, and mycophenolate briefly reduced creatinine to 2.6 mg/dL, followed by worsening...CADs such as amiodarone and haloperidol can induce phospholipidosis via lysosomal accumulation and inhibition of phospholipid degradation...CONCLUSION This appears to be the first reported case linking olanzapine to renal lamellar body formation. Drug-induced phospholipidosis should be considered in patients on CADs who develop unexplained kidney dysfunction."

Chronic Kidney Disease • Fabry Disease • Genetic Disorders • Lung Adenocarcinoma • Lung Cancer • Nephrology • Non Small Cell Lung Cancer • Renal Disease • Solid Tumor

Impact of Dexmedetomidine vs Haloperidol for Sedation on Nursing Workload: Subanalysis of an RCT (SCCM 2026) - "DEX was associated with a reduction in nursing workload in HDUs by shortening bedside care time and decreasing overtime, although it was not associated with improvement in perceived fatigue or break time acquisition. These results suggest the consideration of DEX as a preferred sedative for nocturnal hyperactive delirium in HDUs, where staffing constraints are more pronounced."

CNS Disorders

Delirium Subtypes and Prognosis in Non-Intubated Critically Ill Patients: Subanalysis of an RCT (SCCM 2026) - "We hypothesized that, in non-intubated critically ill patients, delirium subtypes and their prognoses could be more accurately and clearly described. We performed a subanalysis of 393 non-intubated critically ill patients from the DEX-HD trial, which compared dexmedetomidine and haloperidol for sedating nocturnal hyperactive delirium in those who were emergently admitted to two high-dependency units (HDUs) of a tertiary care hospital. In non-intubated critically ill patients in HDUs, mixed-type delirium was the most prevalent and may be associated with poorer prognosis. These findings support the importance of delirium subtyping and suggest that mixed-delirium may require prophylaxis, and targeted interventions."

Clinical • CNS Disorders

A Case of Iodinated Contrast-Induced Thyroid Storm and Respiratory Arrest (SCCM 2026) - "His agitated delirium persisted despite maximum recommended dose of dexmedetomidine and repeated doses of haloperidol, ultimately resolving only after intubation and administration of IV propofol. History revealed noncompliance with methimazole and a previous history of TS...He was treated with IV hydrocortisone, propranolol, and propylthiouracil, with subsequent clinical improvement. Older adults with hyperthyroidism often present to the ED and the growing reliance on iodinated contrast raises concerns for contrast-induced thyrotoxicosis. In individuals with thyroid disease, iodide exposure can trigger clinically significant thyrotoxicosis. Therefore, it is crucial to assess risk factors such as history of thyroid disease/thyroid storm and remain vigilant for signs of thyrotoxicosis following contrast administration, particularly when a patient exhibits an atypical clinical course."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Endocrine Disorders • Grave’s Disease • Immunology • Infectious Disease • Metabolic Disorders • Movement Disorders • Pulmonary Embolism • Respiratory Diseases • TG

Interaction of Fluoxetine and Caffeine in a Patient With Substance-Induced Mania. (PubMed, Bipolar Disord) - "This case highlights a possible interaction between fluoxetine and caffeine contributing to mania and underscores the importance of assessing stimulant use and medication dosing when evaluating new-onset manic symptoms."

Journal • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry

Case Report: Valproate Induced Hyperammonaemic Encephalopathy in a Psychiatric Inpatient. (PubMed, Psychopharmacol Bull) - "He had previously been successfully treated with a combination of antipsychotic (haloperidol) and semi-sodium valproate which were re-prescribed following the index admission to hospital. Early diagnosis and withdrawal of valproate are key in manifesting a prompt and complete recovery. While neurologists are familiar with this complication we believe this is not well known among psychiatrists and therefore worthy of adding this case report to the existing literature."

Journal • Anesthesia • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Infectious Disease • Novel Coronavirus Disease • Psychiatry

Non-Catatonic Mutism as a Presentation of Psychosis: A Case Study. (PubMed, Psychopharmacol Bull) - "Mutism resolved with haloperidol 4 mg daily after initial olanzapine failure, with no overt psychotic symptoms. Non-catatonic mutism may represent isolated psychosis, responsive to antipsychotics. Systematic evaluation is crucial in atypical presentations with psychosocial complexity."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Chronic schizophrenia with aggravation of psychiatric symptoms after cancer surgery: A case report and mini literature review. (PubMed, Ann Palliat Med) - "Patients with comorbid schizophrenia and cancer may present severe psychiatric symptoms in the cancer perioperative period, even if schizophrenia is in a chronic phase. Postoperative delirium, withdrawal delirium, and exacerbation of schizophrenia were speculated to be the possible contributing factors in this case. When patients with cancer also have schizophrenia, oncologists and liaison psychiatrists need to carefully monitor their mental status to prevent interruptions in cancer treatment."

Journal • CNS Disorders • Mental Retardation • Oncology • Ovarian Cancer • Psychiatry • Schizophrenia • Solid Tumor

SHMT2 deficiency disrupts transcriptional regulation through homocysteine-mediated suppression of histone lactylation in Huntington's disease models. (PubMed, J Clin Invest) - "Finally, we demonstrate that the HD clinical drug haloperidol modulates SHMT2 expression and restores histone lactylation, providing a pharmacological tool to probe SHMT2-dependent metabolic and epigenetic regulation in HD models. These findings highlight a metabolic-epigenetic axis as a promising therapeutic target for HD."

Journal • CNS Disorders • Cognitive Disorders • Huntington's Disease • Movement Disorders • AARS1 • SHMT2

Comparison of Antipsychotics in the Treatment of COVID-19-Induced First-Episode Psychosis: A Review of Case Studies. (PubMed, Cureus) - "Olanzapine was the most commonly used single antipsychotic (6, 28.6%), while the combination of haloperidol and aripiprazole was the most frequently used antipsychotic regimen (4, 19.0%). Reported side effects included fatigue, weight gain, akathisia, leukocytosis, and QT-interval prolongation (5, 11.9%), with a relapse rate of (2, 4.8%). This review evaluates the treatment methods for COVID-19 FEP and develops a deeper understanding of various antipsychotics used in managing psychosis and its outcomes."

Journal • Review • CNS Disorders • Fatigue • Infectious Disease • Novel Coronavirus Disease • Psychiatry • Respiratory Diseases

Antipsychotic-induced weight gain in psychosis: causal mediation analysis and feasibility study of causal actionable prediction model development using counterfactuals to target obesity. (PubMed, Br J Psychiatry) - "Our results show that it may be early rather than later weight change that causally mediates antipsychotic-induced weight gain at 1 year. They also demonstrate the potential for causal actionable prediction of counterfactuals for true precision medicine, although this is tempered by the feasibility scope of this study and small sample size. Our results are hypothesis-generating and not yet clinically deployable."

Journal • CNS Disorders • Genetic Disorders • Obesity • Psychiatry • Schizophrenia

Intramuscular Generic Injection (QLG2072) versus Haloperidol in Chinese Patients with Acute Agitation: A Phase 3 Multicenter, Randomized, Double-Blind, Active-Controlled Trial. (PubMed, Drug Des Devel Ther) - P3 | "These findings support its clinical application in Chinese psychiatric populations. ClinicalTrials.gov: NCT05803642."

Clinical • Journal • P3 data • Bipolar Disorder • CNS Disorders • Psychiatry • Schizophrenia

Intravenous Haloperidol, Agitation, and the QTc: Misconceptions and Heuristics. (PubMed, Harv Rev Psychiatry) - "In this perspective, we argue that (1) this practice represents an inappropriate use of a heuristic rather than a necessary risk-benefit calculation, and (2) that our updated understanding of the complex relationships among IVH, QTc, and TdP does not support the use of QTc cut-off values. We address some common misconceptions about the associations among IVH, QTc, and TdP, and discuss how reframing the decision-making process related to this dilemma may improve clinical care."

Journal • CNS Disorders • Psychiatry

Consensus Molecules Associated with Parkinson's Disease. (PubMed, Neurol Int) - "Drugs include L-dopa (49%), carbidopa (63%), benserazide (50%), entacapone (74%), tolcapone (56%), rasagiline (76%), selegiline (46%), pargyline (4%), ropinirole (61%), pramipexole (56%), lisuride (27%), cabergoline (16%), bromocriptine (12%), and zonisamide (9%). Adjunctive therapies include droxidopa (33%), trihexyphenidyl (28%), biperiden (17%), amantadine (24%), memantine (7%), rivastigmine (13%), donepezil (6%), galantamine (4%), domperidone (6%), clonazepam (4%), tetrabenazine (16%), mazindol (13%), quetiapine (6%), and clozapine (4%). Contraindicated drugs include haloperidol (4%), sulpiride (3%), and methyldopa (6%)...Chemical inducers of PD include 6-hydroxydopamine (40%), N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 78%), tetrahydropyridine (77%), probenecid (4%), quinolinic acid (4%), 1,2,3,4-tetrahydroisoquinoline (TIQ, 16%), salsolinol (32%), rotenone (25%), and β-Methylamino-L-alanine (BMAA, 29%). Notably, our study highlights conditional essential..."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease